Tubulis develops antibody-drug conjugates (ADCs) to attack tumors. Munich-based biotech company intends to use the fresh capital to advance development towards clinical evaluation.
"This funding demonstrates that Tubulis is in an excellent position to consolidate the past 20 years of knowledge gained in the field of ADCs and translate it into meaningful therapeutic benefits for patients. We have reached an important turning point in the development of our platform technologies and our pipeline of novel protein-drug conjugates and are now focused on exploring new avenues for the treatment of solid tumors and bringing safe and effective ADCs to patients."
says Dominik Schumacher, CEO and co-founder of Tubulis.
"The capital will enable us to implement our growth strategy, including key pipeline focuses and the combination of our proprietary technologies with biological insights and new mechanisms of action to unlock the true therapeutic potential of targeted therapeutics."
“Tubulis has the potential to play a leading role in the next generation of ADC drug development”
Tubulis has an excellent position in the field of ADCs, says Sofia Ioannidou by Andera Partners.
“We look forward to supporting this talented team in developing innovative ADCs for patients and are confident that Tubulis has the potential to play a leading role in the next generation of ADC drug development.”
